A PHASE I, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ESCALATING DOSES OF DHES0815A IN PATIENTS WITH HER2 POSITIVE BREAST CANCER
Study of Escalating Doses of Study Drug in Patients with HER2 Positive Breast Cancer
Sponsor: Genentech, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR6895
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the safety, tolerability, and the behavior of the drug in your body of an experimental study drug, DHES0815A. The goal is to determine a safe and tolerable dose in patients with cancer and to measure how the body processes the study drug at different dose levels.
This study is closed
Investigator
Kevin Kalinsky, MD, MS
Do You Qualify?
Are you at least 18 years of age? Yes No
Do you have a diagnosis of locally advanced or metastatic HER2 positive breast cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE